- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07938385
Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) (CHIMERA)
Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle.
The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy.
Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection.
If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Anna Dr Wilkins, FRCR, MRCP, MB
- Phone Number: 4020 0208 642 6011
- Email: Anna.Wilkins@icr.ac.uk
Study Contact Backup
- Name: Abigail Ms Crowhurst, Masters
- Phone Number: 4020 0208 642 6011
- Email: Abigail.Crowhurst@rmh.nhs.uk
Study Locations
-
-
-
London, United Kingdom, SW3 6JJ
- Recruiting
- Royal Marsden NHS Foundation Trust
-
Contact:
- Anna Wilkins, FRCR, MRCP, MB
- Phone Number: 4020 0208 642 6011
- Email: Anna.Wilkins@icr.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients receiving any type of radiotherapy are eligible for CHIMERA with lung, head and neck, bladder, cervical or rectal cancer
Description
Inclusion Criteria:
- Patients receiving any type of radiotherapy are eligible for CHIMERA provided they are at least 18 years of age and can attend routine follow up appointments
Exclusion Criteria:
- As immunodeficiency due to HIV/AIDS or other infective or autoimmune immunological conditions may impact feasibility and results of immune profiling, immunosuppressed patients due to infection such as HIV, Hepatitis B/C are excluded.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Lung cancer 1
5 patients with peripheral lung tumours and 5 patients with central lung tumours receiving radical radiotherapy without chemotherapy will be recruited. |
Tissue and blood sample collection |
|
Lung cancer 2
12 patients. To establish the feasibility of ctDNA profiling before, during and after radiotherapy for non-small cell lung cancer (NSCLC). |
Tissue and blood sample collection |
|
Head and Neck cancer
This pilot includes 12 patients (6 HPV+ and 6 HPV-) head and neck cancer patients |
Tissue and blood sample collection |
|
Cervical cancer
12 patients to establish the feasibility of tumour TCR-Seq profiling before, during and after radiotherapy for cervix cancer. This includes patients receiving either radiotherapy or chemoradiotherapy |
Tissue and blood sample collection |
|
Bladder cancer 1
12 patients to establish the feasibility of collecting urine-derived lymphocytes suitable for flow cytometry before, during and after chemoradiotherapy. |
Tissue and blood sample collection |
|
Bladder cancer 2
24 patients To establish the feasibility of tumour TCR-Seq profiling before, during and after chemoradiotherapy for bladder cancer, in comparison to a cystectomy sample. |
Tissue and blood sample collection |
|
Rectal cancer 1
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during chemoradiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
|
Rectal cancer 2
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during radiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The feasibility of measuring the change in immune cell repertoire before, during and after radiotherapy
Time Frame: defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
establishment of proof-of-principle that immune changes occur during and after radiotherapy. Measurement tool is multiparametric flow cytometry immune panel. |
defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy
Time Frame: Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy. Measurement tool is targeted DNA sequencing with reference to baseline tumour. |
Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Respiratory Tract Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Uterine Diseases
- Genital Diseases, Female
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Uterine Neoplasms
- Rectal Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Uterine Cervical Neoplasms
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Immunologic Techniques
- Immunologic Tests
- Histocompatibility Testing
Other Study ID Numbers
- 4893
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
No plan
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.